JP2006509764A5 - - Google Patents

Download PDF

Info

Publication number
JP2006509764A5
JP2006509764A5 JP2004555693A JP2004555693A JP2006509764A5 JP 2006509764 A5 JP2006509764 A5 JP 2006509764A5 JP 2004555693 A JP2004555693 A JP 2004555693A JP 2004555693 A JP2004555693 A JP 2004555693A JP 2006509764 A5 JP2006509764 A5 JP 2006509764A5
Authority
JP
Japan
Prior art keywords
triglycerides
dgat1
diacylglycerols
diacylglycerol
negate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004555693A
Other languages
English (en)
Other versions
JP3988830B2 (ja
JP2006509764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/037574 external-priority patent/WO2004047755A2/en
Publication of JP2006509764A publication Critical patent/JP2006509764A/ja
Publication of JP2006509764A5 publication Critical patent/JP2006509764A5/ja
Application granted granted Critical
Publication of JP3988830B2 publication Critical patent/JP3988830B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

ジアシルグリセロールからのトリグリセリドの合成を触媒するのに複数の酵素が寄与するという知見は重要である。なぜなら、それはこの生化学的反応の1つの触媒メカニズムを調節して、悪い副作用を最小限に抑えつつ、個体における治療効果をもたらす機会を与えるからである。例えば、DGAT1のヒトホモログの活性を特異的に阻害することによって、ジアシルグリセロールのトリグリセリドへの転換を阻害する化合物は、体内におけるトリグリセリドの濃度および吸収を低下させる際に、肥満症、インスリン抵抗性症候群および顕性II型糖尿病、うっ血性心不全およびアテローム硬化症、そして癌治療の結果生じたトリグリセリドの代謝異常により生じる病気の発症を治療によって無効にする用途に使えるであろう。
JP2004555693A 2002-11-22 2003-11-21 縮合二環式窒素含有複素環 Expired - Fee Related JP3988830B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42860002P 2002-11-22 2002-11-22
PCT/US2003/037574 WO2004047755A2 (en) 2002-11-22 2003-11-21 Fused bicyclic nitrogen-containing heterocycles

Publications (3)

Publication Number Publication Date
JP2006509764A JP2006509764A (ja) 2006-03-23
JP2006509764A5 true JP2006509764A5 (ja) 2006-09-07
JP3988830B2 JP3988830B2 (ja) 2007-10-10

Family

ID=32393428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004555693A Expired - Fee Related JP3988830B2 (ja) 2002-11-22 2003-11-21 縮合二環式窒素含有複素環

Country Status (15)

Country Link
US (2) US7244727B2 (ja)
EP (1) EP1562956A4 (ja)
JP (1) JP3988830B2 (ja)
KR (1) KR100772297B1 (ja)
CN (1) CN1753897A (ja)
AU (1) AU2003293006A1 (ja)
BR (1) BR0315688A (ja)
CA (1) CA2514473C (ja)
IL (1) IL168497A0 (ja)
MX (1) MXPA05005425A (ja)
NO (1) NO20052923L (ja)
NZ (1) NZ539952A (ja)
RU (1) RU2342388C2 (ja)
WO (1) WO2004047755A2 (ja)
ZA (1) ZA200503823B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7100634B2 (ja) 2016-10-14 2022-07-13 ヘプタレス セラピューティクス リミテッド Cns疾患及び疼痛の治療におけるムスカリンm1及び/又はm4受容体の調節因子として活性を有する複素環式化合物。

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
MXPA05005425A (es) * 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2007519605A (ja) * 2004-01-30 2007-07-19 日本たばこ産業株式会社 食欲抑制薬
AU2005295453A1 (en) * 2004-10-15 2006-04-27 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2006045096A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
NZ587106A (en) 2004-12-14 2012-03-30 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
WO2006082010A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Inhibitors of diacylglycerol acyltransferase (dgat)
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
WO2006120125A1 (en) 2005-05-10 2006-11-16 F. Hoffmann-La Roche Ag Diacylglycerol acyltransferase inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7723342B2 (en) * 2005-05-17 2010-05-25 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2610188A1 (en) * 2005-06-11 2006-12-21 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007060140A2 (en) 2005-11-28 2007-05-31 F. Hoffmann-La Roche Ag Inhibitors of diacyglycerol acyltransferase (dgat)
JPWO2007063839A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 シクロヘキサン誘導体
US7749997B2 (en) 2005-12-22 2010-07-06 Astrazeneca Ab Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
PE20070854A1 (es) 2006-01-20 2007-09-10 Schering Corp Compuestos heterociclos como agonistas del receptor de acido nicotinico
KR20080103584A (ko) * 2006-03-30 2008-11-27 아사히 가세이 파마 가부시키가이샤 치환 이환식 환상 유도체 및 그 용도
ES2430115T3 (es) 2006-03-31 2013-11-19 Novartis Ag Inhibidor de DGAT
CA2651663A1 (en) 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US8084478B2 (en) 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
JP2009539818A (ja) 2006-06-08 2009-11-19 アストラゼネカ アクチボラグ ベンゾイミダゾールおよび糖尿病の処置のためのその使用
GB0611506D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
AU2007298286B2 (en) 2006-09-19 2011-02-03 Daiichi Sankyo Company, Limited Pyrazolopyrimidine derivative
JP2010511058A (ja) 2006-11-29 2010-04-08 アボット・ラボラトリーズ ジアシルグリセロールo−アシルトランスフェラーゼ1型酵素の阻害薬
WO2008073865A2 (en) * 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
EP2120911A1 (en) * 2007-02-15 2009-11-25 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
CN101678011B (zh) 2007-05-16 2012-07-18 默沙东公司 螺氮茚酮化合物
US8058299B2 (en) * 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) * 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) * 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US20090099201A1 (en) * 2007-05-22 2009-04-16 David Robert Bolin Diacylglycerol Acyltransferase Inhibitors
WO2008148851A1 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン/ピペラジン誘導体
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066911A1 (es) 2007-06-08 2009-09-23 Janssen Pharmaceutica Nv Derivados de piperidina / piperazina
US20090036425A1 (en) * 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
KR20100099738A (ko) 2007-12-20 2010-09-13 아스트라제네카 아베 Dgat1 억제제로서의 카르바모일 화합물 190
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
JP5579170B2 (ja) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Dgat阻害剤とppar作動薬を含有する薬剤組み合わせ物
ES2532402T3 (es) 2008-06-26 2015-03-26 Resverlogix Corporation Métodos de preparación de derivados de quinazolinona
US8211884B2 (en) * 2008-08-06 2012-07-03 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2010039801A2 (en) * 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2367817A4 (en) * 2008-12-03 2012-05-09 Via Pharmaceuticals Inc INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE ENZYME
EP2378878A4 (en) * 2008-12-17 2012-08-01 Via Pharmaceuticals Inc INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
TW201040174A (en) 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
WO2010089686A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
WO2010098344A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 三環性ピラゾロピリミジン誘導体
AR076126A1 (es) * 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
EP2805951B1 (en) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
JP5813626B2 (ja) 2009-04-22 2015-11-17 レスバーロジックス コーポレイション 新規抗炎症剤
BRPI1016109A2 (pt) 2009-06-19 2016-05-17 Astrazeneca Ab "composto, composição farmacêutica, e, processo para preparar um composto"
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2011031628A1 (en) 2009-09-14 2011-03-17 Schering Corporation Inhibitors of diacylglycerol acyltransferase
MX2012004078A (es) 2009-10-09 2012-07-25 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP2810945A1 (en) 2010-08-23 2014-12-10 Daiichi Sankyo Company, Limited Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative
CA2809388A1 (en) 2010-08-23 2012-03-01 Daiichi Sankyo Company, Limited Crystal of a free tricyclic pyrazolopyrimidine derivative
KR20130013199A (ko) 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR102011641B1 (ko) 2011-11-01 2019-08-19 리스버로직스 코퍼레이션 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형
JP6083818B2 (ja) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited ムスカリンm1受容体アゴニスト
FR2986232B1 (fr) * 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
WO2013157792A1 (en) * 2012-04-17 2013-10-24 Hanmi Pharm. Co., Ltd. Bicyclic heteroaryl derivative and pharmaceutical composition comprising same
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
WO2014054053A1 (en) 2012-10-03 2014-04-10 Advinus Therapeutics Limited Spirocyclic compounds, compositions and medicinal applications thereof
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014081995A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015066697A1 (en) * 2013-11-04 2015-05-07 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
DK3674302T3 (da) 2014-04-23 2023-04-03 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
CN105218561B (zh) * 2014-06-25 2018-10-30 上海艾力斯医药科技有限公司 稠合嘧啶环衍生物、其制备方法及应用
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
CN104496795B (zh) * 2014-12-12 2016-09-14 重庆博腾制药科技股份有限公司 一种dgat-1抑制剂中间体的制备方法
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017205432A1 (en) * 2016-05-23 2017-11-30 Dai Lu Functionalized pyrano[2,3-d]pyrimidin-7-one derivatives and methods for their preparation and use
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
JP2019528300A (ja) * 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
US11365191B2 (en) 2018-02-28 2022-06-21 Dart Neuroscience, Llc Substituted cyclohexyl compounds as NOP inhibiiors
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPH05213985A (ja) 1992-02-10 1993-08-24 Mitsubishi Kasei Corp ピロールカルボン酸コエンザイムa誘導体
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
JP2001097979A (ja) * 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
JP2002284741A (ja) 2001-03-23 2002-10-03 Kitasato Inst:The ローズリピン誘導体
IL160253A0 (en) 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
KR100460438B1 (ko) 2001-12-01 2004-12-08 한국생명공학연구원 아실 코에이:디아실글리세롤 아실트랜스퍼라제활성저해제인 신규 폴리아세틸렌계 화합물 및 이의 제조방법
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Dgat阻害剤
MXPA05005425A (es) * 2002-11-22 2005-11-23 Japan Tobacco Inc Heterociclos que contienen nitrogeno, biciclicos, fusionados.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7100634B2 (ja) 2016-10-14 2022-07-13 ヘプタレス セラピューティクス リミテッド Cns疾患及び疼痛の治療におけるムスカリンm1及び/又はm4受容体の調節因子として活性を有する複素環式化合物。

Similar Documents

Publication Publication Date Title
JP2006509764A5 (ja)
RU2462456C2 (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
Fan et al. Metabolic regulation of histone post-translational modifications
UA104987C2 (uk) Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
Thomas Involvement of HDAC1 and HDAC3 in the pathology of polyglutamine disorders: therapeutic implications for selective HDAC1/HDAC3 inhibitors
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
IT1299266B1 (it) Inibitori reversibili della carnitina palmitoil trasferasi
JP2007529507A5 (ja)
John et al. Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2
FI3164125T3 (fi) Menetelmiä ja koostumuksia liikalihavuuden hoitamiseksi, painonnousun ehkäisemiseksi, painonpudotuksen edistämiseksi, laihtumisen edistämiseksi tai diabeteksen hoitamiseksi tai sen kehittymisen ehkäisemiseksi
Takahashi et al. Chemical synthesis of an indomethacin ester prodrug and its metabolic activation by human carboxylesterase 1
WO2004041165A3 (en) Compounds for the treatment of metabolic disorders
Streck et al. Effects of mood stabilizers on brain energy metabolism in mice submitted to an animal model of mania induced by paradoxical sleep deprivation
Fujimoto et al. Discovery of 3, 5-diphenyl-4-methyl-1, 3-oxazolidin-2-ones as novel, potent, and orally available Δ-5 desaturase (D5D) inhibitors
WO2007124383A3 (en) 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members
Rothenhäusler et al. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker
NO20054380L (no) Arylsykloalkylderivater med forgrenede sidekjeder som PPAR-reseptormodulatorer, deres fremstilling og deres anvendelse som legemiddel
MY156174A (en) 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
CN104415023A (zh) 预防或/和治疗胰岛素抵抗及相关病症的组合物
Ohsawa et al. Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease
CA2750074A1 (en) Use of cardiotrophin-1 for the treatment of metabolic diseases
WO2003087818A3 (en) Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction
JP2008505134A5 (ja)
Xiao et al. Crystal structure of methyl 4-acetoxy-3-methoxybenzoate, C11H12O5
JP2004532866A5 (ja)